67,025 Shares in Hologic, Inc. (NASDAQ:HOLX) Bought by Benson Investment Management Company Inc.

Benson Investment Management Company Inc. bought a new position in shares of Hologic, Inc. (NASDAQ:HOLX) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 67,025 shares of the medical equipment provider’s stock, valued at approximately $4,832,000. Hologic comprises approximately 2.0% of Benson Investment Management Company Inc.’s investment portfolio, making the stock its 29th largest holding.

Several other hedge funds and other institutional investors have also recently bought and sold shares of HOLX. Wolff Wiese Magana LLC bought a new position in shares of Hologic during the third quarter worth about $25,000. General Partner Inc. bought a new stake in Hologic in the fourth quarter valued at approximately $26,000. Groupama Asset Managment increased its position in Hologic by 9.9% during the 3rd quarter. Groupama Asset Managment now owns 33,177 shares of the medical equipment provider’s stock valued at $27,000 after purchasing an additional 2,999 shares during the period. Sunbelt Securities Inc. bought a new position in Hologic during the 2nd quarter worth approximately $37,000. Finally, First Horizon Advisors Inc. lifted its position in shares of Hologic by 38.3% in the 3rd quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider’s stock worth $39,000 after purchasing an additional 134 shares during the period. 94.73% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms have recently weighed in on HOLX. Raymond James increased their price objective on shares of Hologic from $93.00 to $95.00 and gave the stock an “outperform” rating in a research report on Tuesday, November 5th. JPMorgan Chase & Co. increased their price target on Hologic from $92.00 to $94.00 and gave the stock an “overweight” rating in a report on Tuesday, November 5th. Citigroup downgraded Hologic from a “buy” rating to a “neutral” rating and dropped their price objective for the company from $95.00 to $85.00 in a research note on Tuesday, October 1st. Jefferies Financial Group started coverage on Hologic in a research report on Tuesday, December 10th. They set a “hold” rating and a $85.00 target price on the stock. Finally, Leerink Partners lowered their target price on Hologic from $95.00 to $90.00 and set an “outperform” rating for the company in a report on Tuesday, October 8th. Seven analysts have rated the stock with a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Hologic presently has a consensus rating of “Moderate Buy” and a consensus target price of $88.92.

Hologic Stock Performance

Shares of HOLX stock opened at $70.29 on Tuesday. Hologic, Inc. has a 12 month low of $69.46 and a 12 month high of $84.67. The firm has a market capitalization of $15.95 billion, a PE ratio of 21.11, a price-to-earnings-growth ratio of 2.32 and a beta of 0.97. The firm has a fifty day simple moving average of $75.61 and a two-hundred day simple moving average of $78.53. The company has a current ratio of 3.69, a quick ratio of 3.03 and a debt-to-equity ratio of 0.49.

Hologic (NASDAQ:HOLX) last posted its earnings results on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share for the quarter, hitting analysts’ consensus estimates of $1.01. The company had revenue of $987.90 million for the quarter, compared to analyst estimates of $978.25 million. Hologic had a net margin of 19.59% and a return on equity of 19.79%. The firm’s revenue was up 4.5% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.89 EPS. Analysts forecast that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

Insider Buying and Selling

In other Hologic news, COO Essex D. Mitchell sold 24,856 shares of the company’s stock in a transaction dated Wednesday, December 4th. The shares were sold at an average price of $76.34, for a total value of $1,897,507.04. Following the completion of the sale, the chief operating officer now directly owns 27,957 shares of the company’s stock, valued at approximately $2,134,237.38. This represents a 47.06 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. 1.75% of the stock is currently owned by corporate insiders.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.